Abstract:Glucocerenrosidase1 (GBA1) mutations cause disruptions in endoplasmic reticulum (ER) and lysosome‐related proteostasis pathways in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons. Severe GBA1 mutations lead to increased ER stress (increased binding immunoglobulin protein (BiP) and protein disulfide isomerase (PDI) levels), total ubiquitination rates, and unfolded protein response (UPR). Defective chaperone‐mediated autophagy (decreased heat‐shock cognate protein 70 (HSC70) levels and decreased co‐localization of lysosomal‐associated membrane protein 2A (LAMP2A) and HSC70) is observed in iPSC‐derived dopaminergic neurons with mild homozygous GBA1 mutations. Decreased autophagosome formation (decreased microtubule‐associated protein light chain 3A (LC3) levels) is observed in iPSC‐derived dopaminergic neurons with homozygous N370S and D409H GBA1 mutations, while fusion defects (decreased lysosomal‐associated membrane protein 1 (LAMP1) and LC3 co‐localization) are observed in neurons with homozygous L444P GBA1 mutation. Severe GBA1 mutations trigger the accumulation of monomeric and oligomeric forms of α‐synuclein. GBA1 mutations increase the release of α‐synuclein from iPSC‐derived dopaminergic neurons. Glucocerebrosidase 1 (GBA1) mutations are the most important genetic risk factors for Parkinson's disease (PD). Clinically, mild (e.g., p.N370S) and severe (e.g., p.L444P and p.D409H) GBA1 mutations have different PD phenotypes, with differences in age at disease onset, progression, and the severity of motor and non‐motor symptoms. We hypothesize that GBA1 mutations cause the accumulation of α‐synuclein by affecting the cross‐talk between cellular protein degradation mechanisms, leading to neurodegeneration. Accordingly, we tested whether mild and severe GBA1 mutations differentially affect the degradation of α‐synuclein via the ubiquitin–proteasome system (UPS), chaperone‐mediated autophagy (CMA), and macroautophagy and differentially cause accumulation and/or release of α‐synuclein. Our results demonstrate that endoplasmic reticulum (ER) stress and total ubiquitination rates were significantly increased in cells with severe GBA1 mutations. CMA was found to be defective in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons with mild GBA1 mutations, but not in those with severe GBA1 mutations. When examining macroautophagy, we observed reduced formation of autophagosomes in cells with the N370S and D409H GBA1 mutations and impairments in autophagosome–lysosome fusion in cells with the L444P GBA1 mutation. Accordingly, severe GBA1 mutations were found to trigger the accumulation and release of oligomeric α‐synuclein in iPSC‐derived dopaminergic neurons, primarily as a result of increased ER stress and defective macroautophagy, while mild GBA1 mutations affected CMA, which is mainly responsible for the degradation of the monomeric form of α‐synuclein. Overall, our findings provide new insight into the molecular basis of the clinical variability in PD associated with different GBA1 mutations.

Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson′s disease and Dementia with Lewy bodies

Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration

Gba1 E326K renders motor and non-motor symptoms with pathologic α-syn, tau and glial activation

GBA1 mutations alter neuronal firing and structure, regulating VGLUT2 and CRYAB in dopamine neurons

Variant‐specific effects of GBA1 mutations on dopaminergic neuron proteostasis

α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism

Glucocerebrosidase deficiency leads to neuropathology via cellular immune activation

GBA-AAV mitigates sleep disruptions and motor deficits in mice with REM sleep behavior disorder

Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients

iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis

Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

GBA1-Associated Parkinson's Disease Is a Distinct Entity

Role of GBA variants in Lewy body disease neuropathology

Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles

Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease

AAV delivery of GBA1 suppresses alpha-synuclein accumulation in Parkinson's disease models and restores motor dysfunction in a Gaucher's disease model

Glucocerebrosidase and its relevance to Parkinson disease

GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice

Upregulation of NFE2L1 reduces ROS levels and α-synuclein aggregation caused by GBA1 knockdown

Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease